Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Stephen E. Fremes"'
Autor:
Jae K. Oh, G. Michael Deeb, G. Chad Hughes, Steven J. Yakubov, Stephen E. Fremes, Michael J. Reardon, Thomas G. Gleason, Stuart J. Head, Thomas Modine, Jian Huang, J. Kevin Harrison, M. Erwin Tan, Ka Yan Lam, Pim A.L. Tonino
Publikováno v:
The Annals of Thoracic Surgery. 113:616-622
Randomized clinical trials have shown that transcatheter aortic valve replacement is noninferior to surgery in low surgical risk patients. We compared outcomes in patients treated with a sutured (stented or stentless) or sutureless surgical valve fro
Publikováno v:
The Journal of Thoracic and Cardiovascular Surgery. 163:2053-2055
Autor:
Derrick Y. Tam, Harindra C. Wijeysundera, David Cohen, John G. Webb, Mario Gaudino, David Naimark, Stephen E. Fremes
Publikováno v:
Circulation. 142:354-364
Background: Recent clinical trial results showed that transcatheter aortic valve replacement (TAVR) is noninferior and may be superior to surgical aortic valve replacement (SAVR) for mortality, stroke, and rehospitalization. However, the impact of tr
Autor:
Joanna Chikwe, Harindra C. Wijeysundera, Paymon M. Azizi, Derrick Y. Tam, Mario Gaudino, Stephen E. Fremes
Publikováno v:
European Heart Journal - Quality of Care and Clinical Outcomes. 7:556-563
Aims The economic value of transcatheter aortic valve replacement (TAVR) in low surgical risk patients with severe, symptomatic aortic stenosis is not known. Our objective was to determine the cost-effectiveness of balloon-expandable TAVR and self-ex
Autor:
Maral Ouzounian, Mario Gaudino, Joanna Chikwe, Stephen E. Fremes, Peter C. Austin, Derrick Y. Tam, Harindra C. Wijeysundera, Christoffer Dharma, Rodolfo V. Rocha
Publikováno v:
JACC: Cardiovascular Interventions. 13:765-774
Objectives The aim of this study was to compare early and late outcomes between redo surgical aortic valve replacement (AVR) and valve-in-valve (ViV) transcatheter AVR. Background Published studies to date comparing redo surgical AVR (RS) with ViV tr
Autor:
Derrick Y. Tam, Maral Ouzounian, Rodolfo V. Rocha, Wanqing Yu, Ahmad Makhdoum, Stephen E. Fremes
Publikováno v:
Canadian Journal of Cardiology. 35:782-790
Aortic root enlargement (ARE) may be an important adjunct to aortic valve replacement (AVR) to prevent patient-prosthesis mismatch and facilitate future valve-in-valve transcatheter AVR (TAVR). However, the early safety and late benefits of adding su
Autor:
Jan O. Friedrich, Harindra C. Wijeysundera, Stephen E. Fremes, Danny Dvir, Thin Xuan Vo, Derrick Y. Tam
Publikováno v:
Catheterization and Cardiovascular Interventions. 92:1404-1411
Objective To determine the safety and efficacy of valve-in-valve transcatheter aortic valve replacement (ViV) versus redo surgical aortic valve replacement (SAVR) for the treatment of previously failed aortic bioprostheses. Background Valve-in-valve
Autor:
Maral Ouzounian, C Dharma, Stephen E. Fremes, Derrick Y. Tam, Harindra C. Wijeysundera, Rodolfo V. Rocha, Peter C. Austin
Publikováno v:
European Heart Journal. 40
Background While the gold standard for the management of failed previous biological prosthesis was redo surgical aortic valve replacement (SAVR), valve-in-valve (ViV) transcatheter AVR (TAVR) has emerged as a less invasive option. Published studies c
Autor:
Dennis T. Ko, Derrick Y. Tam, Rodolfo V. Rocha, Thin Xuan Vo, Stephen E. Fremes, Jan O. Friedrich, Harindra C. Wijeysundera
Publikováno v:
Canadian Journal of Cardiology. 33:1171-1179
Background Transcatheter aortic valve replacement (TAVR) has emerged as the treatment of choice for patients with severe aortic stenosis at high surgical risk; the role of TAVR compared with surgical aortic valve replacement (SAVR) in the low-interme
Autor:
Nevena Zivkovic, Effat Rezaei, Sami Alnasser, Yaron Arbel, Stephen E. Fremes, Asim N. Cheema, Ariel Finkelstein, Dhruven Mehta, Harindra C. Wijeysundera, Sam Radhakrishnan
Publikováno v:
BMC Cardiovascular Disorders, Vol 17, Iss 1, Pp 1-9 (2017)
BMC Cardiovascular Disorders
BMC Cardiovascular Disorders
Background Most patients undergoing Transcatheter aortic valve implantation (TAVR) are elderly with significant co-morbidities and there is limited information available regarding factors that influence length of stay (LOS) post-procedure. The aim of